Diagnostic Approach and Management of Urethritis

Diagnostic Evaluation

The Centers for Disease Control and Prevention (CDC) recommends that the diagnosis of urethritis requires objective evidence, including at least one of the following: visible urethral discharge, ≥10 white blood cells per high-power field in first-void urine, or a positive leukocyte esterase test on first-void urine, in a patient with symptoms of urethritis 1
The presence of a "wet feeling in underwear" likely represents urethral discharge, which is a hallmark of urethritis, and the absence of dysuria does not exclude urethritis, as many infections are asymptomatic or present with minimal symptoms 1

The CDC recommends starting treatment immediately without waiting for test results, with doxycycline 100 mg orally twice daily for 7 days as the first-line treatment for nongonococcal urethritis (NGU), and adding ceftriaxone 500 mg IM single dose or cefixime 400 mg orally single dose to cover gonorrhea if testing is unavailable 1
Alternative regimens for patients with contraindications to doxycycline include erythromycin base 500 mg orally 4 times daily for 7 days or erythromycin ethylsuccinate 800 mg orally 4 times daily for 7 days 1

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) should be considered if symptoms persist beyond 3 months, and is characterized by pain in the perineum, suprapubic region, testicles, or tip of penis, exacerbated by urination or ejaculation, and a sense of incomplete bladder emptying 2, 1
Interstitial cystitis/bladder pain syndrome (IC/BPS) can present with bladder/pelvic pain, pressure, or discomfort, and urinary frequency and urgency, but is less likely in young males with acute symptoms 2, 3

Patients should return only if symptoms persist or recur after completing therapy, and if no improvement is seen within 3 days of starting treatment, the diagnosis should be re-evaluated 1
If symptoms continue beyond 3 months despite appropriate treatment, consideration should be given to chronic prostatitis/chronic pelvic pain syndrome, and referral to urology for further evaluation may be necessary 1, 2

All sexual partners within the preceding 60 days require evaluation and empiric treatment, with the same chlamydia-effective regimen as the patient, even if the patient's specific etiology is unknown 1

The Centers for Disease Control and Prevention recommends treating patients with nongonococcal urethritis (NGU) empirically with doxycycline 100 mg orally twice daily for 7 days, as the most common causes of NGU (Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma genitalium, and Trichomonas vaginalis) may not be detected by standard STI panels 4, 5
Urethritis is confirmed by mucopurulent/purulent discharge, ≥5 white blood cells per oil immersion field on urethral Gram stain, or ≥10 white blood cells per high-power field in first-void urine 4
C. trachomatis causes only 23-55% of NGU cases, with the proportion declining over time 4, 5
Ureaplasma urealyticum accounts for 20-40% of NGU cases, and Trichomonas vaginalis causes 2-5% 5, 6, 7

The American College of Physicians recommends doxycycline 100 mg orally twice daily for 7 days as first-line treatment for NGU 4, 5
Alternative regimens for patients intolerant of doxycycline include erythromycin base 500 mg orally 4 times daily for 7 days or erythromycin ethylsuccinate 800 mg orally 4 times daily for 7 days 5, 8

The Centers for Disease Control and Prevention recommends that sexual partners be evaluated and treated, with partners with last sexual contact within 30 days of symptom onset being prioritized 5, 8, 9
Partners with contact within 60 days of diagnosis should be evaluated and treated if the patient is asymptomatic 5, 8, 9

Patients should return for evaluation only if symptoms persist or recur after completing therapy 5, 8
Failure to improve within 3 days of starting treatment requires re-evaluation of diagnosis and therapy 10, 11